Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APRE Aprea Therapeutics	$1.58 -1.3%	$1.72	$1.41 ▼ $5.01	$9.20M	1.29	37,978 shs	43,476 shs
ITRM Iterum Therapeutics	$0.68 -5.2%	$0.88	$0.66 ▼ $3.02	$30.51M	2.85	604,339 shs	983,987 shs
MRSN Mersana Therapeutics	$7.65	$7.81	$5.21 ▼ $70.75	$38.17M	0.83	159,738 shs	52,342 shs
OKUR OnKure Therapeutics	$2.75 -2.5%	$2.41	$1.70 ▼ $20.00	$37.15M	0.4	111,810 shs	25,752 shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APRE Aprea Therapeutics	-2.74%	-3.03%	-15.34%	-6.98%	-54.42%
ITRM Iterum Therapeutics	-3.09%	-17.13%	-10.16%	-23.70%	-40.41%
MRSN Mersana Therapeutics	-1.29%	+3.66%	-5.00%	-15.00%	-80.38%
OKUR OnKure Therapeutics	-0.35%	+0.71%	+22.08%	+24.78%	+281,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
APRE Aprea Therapeutics	2.8917 of 5 stars	3.5	5.0	0.0	0.6	0.8	1.3
ITRM Iterum Therapeutics	1.8033 of 5 stars	3.5	3.0	0.0	0.6	1.7	0.0
MRSN Mersana Therapeutics	4.1727 of 5 stars	3.5	4.0	4.1	1.7	2.5	0.0
OKUR OnKure Therapeutics	2.9516 of 5 stars	3.6	0.0	0.0	1.9	2.5	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APRE Aprea Therapeutics	3.00	Buy	$15.50	881.01% Upside
ITRM Iterum Therapeutics	3.00	Buy	$9.00	1,217.14% Upside
MRSN Mersana Therapeutics	3.00	Buy	$56.60	639.87% Upside
OKUR OnKure Therapeutics	3.14	Buy	$32.33	1,075.76% Upside

Current Analyst Ratings Breakdown

Latest APRE, ITRM, MRSN, and OKUR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/26/2025	OKUR OnKure Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$34.00
8/14/2025	MRSN Mersana Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$250.00 ➝ $36.00
8/14/2025	MRSN Mersana Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$125.00 ➝ $30.00
8/13/2025	MRSN Mersana Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$17.00
8/13/2025	OKUR OnKure Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
6/26/2025	APRE Aprea Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$11.00
6/3/2025	MRSN Mersana Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform

(Data available from 8/26/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APRE Aprea Therapeutics	N/A	N/A	N/A	N/A	$3.55 per share	N/A
ITRM Iterum Therapeutics	N/A	N/A	N/A	N/A	($0.15) per share	N/A
MRSN Mersana Therapeutics	$40.50M	0.94	N/A	N/A	($1.92) per share	-3.98
OKUR OnKure Therapeutics	N/A	N/A	N/A	N/A	$7.78 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APRE Aprea Therapeutics	-$12.96M	-$2.32	N/A	N/A	N/A	-1,645.01%	-78.90%	-62.67%	11/6/2025 (Estimated)
ITRM Iterum Therapeutics	-$24.77M	-$0.85	N/A	∞	N/A	N/A	N/A	-65.01%	11/13/2025 (Estimated)
MRSN Mersana Therapeutics	-$69.19M	-$14.62	N/A	N/A	N/A	-212.94%	-990.16%	-54.85%	11/12/2025 (Estimated)
OKUR OnKure Therapeutics	-$52.67M	-$4.80	N/A	N/A	N/A	N/A	-60.52%	-55.43%	11/6/2025 (Estimated)

Latest APRE, ITRM, MRSN, and OKUR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	MRSN Mersana Therapeutics	-$3.75	-$4.08	-$0.33	-$4.87	$6.06 million	$3.06 million
8/12/2025	Q2 2025	APRE Aprea Therapeutics	-$0.77	-$0.53	+$0.24	-$0.53	N/A	$0.12 million
8/12/2025	Q2 2025	OKUR OnKure Therapeutics	-$1.23	-$1.14	+$0.09	-$1.14	N/A	N/A
8/5/2025	Q2 2025	ITRM Iterum Therapeutics	-$0.13	-$0.16	-$0.03	-$0.16	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
APRE Aprea Therapeutics	N/A	N/A	N/A	N/A	N/A
ITRM Iterum Therapeutics	N/A	N/A	N/A	N/A	N/A
MRSN Mersana Therapeutics	N/A	N/A	N/A	N/A	N/A
OKUR OnKure Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APRE Aprea Therapeutics	N/A	5.34	5.34
ITRM Iterum Therapeutics	N/A	2.69	2.52
MRSN Mersana Therapeutics	N/A	1.35	1.35
OKUR OnKure Therapeutics	N/A	11.13	11.13

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
APRE Aprea Therapeutics	34.19%
ITRM Iterum Therapeutics	9.21%
MRSN Mersana Therapeutics	93.92%
OKUR OnKure Therapeutics	90.98%

Insider Ownership

Company	Insider Ownership
APRE Aprea Therapeutics	13.63%
ITRM Iterum Therapeutics	2.40%
MRSN Mersana Therapeutics	13.00%
OKUR OnKure Therapeutics	2.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
APRE Aprea Therapeutics	7	5.83 million	5.03 million	No Data
ITRM Iterum Therapeutics	10	44.66 million	43.59 million	Not Optionable
MRSN Mersana Therapeutics	150	4.99 million	4.34 million	Optionable
OKUR OnKure Therapeutics	N/A	13.51 million	11.11 million	N/A

APRE, ITRM, MRSN, and OKUR Headlines

Recent News About These Companies

Brokerages Set OnKure Therapeutics, Inc. (NASDAQ:OKUR) PT at $32.33

August 22, 2025 | americanbankingnews.com

Companies Like OnKure Therapeutics (NASDAQ:OKUR) Could Be Quite Risky

August 19, 2025 | finance.yahoo.com

Companies Like OnKure Therapeutics (NASDAQ:OKUR) Could Be Quite Risky

August 19, 2025 | finance.yahoo.com

Leerink Partnrs Has Positive Forecast for OKUR Q3 Earnings

August 16, 2025 | americanbankingnews.com

Analysts Offer Insights on Healthcare Companies: OnKure Therapeutics (OKUR) and AbCellera Biologics (ABCL)

August 15, 2025 | theglobeandmail.com

OnKure Therapeutics reports Q2 EPS ($1.14), consensus ($1.25)

August 12, 2025 | msn.com

OnKure Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Business Update

August 12, 2025 | globenewswire.com

OKUR OnKure Therapeutics, Inc.

June 12, 2025 | seekingalpha.com

Buy Rating for OnKure Therapeutics Driven by Promising Developments in Metastatic Breast Cancer Treatment and Strong Financial Position

June 3, 2025 | tipranks.com

Insider Selling: OnKure Therapeutics (NASDAQ:OKUR) Major Shareholder Sells 1,813,439 Shares of Stock

May 20, 2025 | insidertrades.com

OnKure Therapeutics (NASDAQ:OKUR) Major Shareholder Cormorant Asset Management, Lp Sells 24,300 Shares

May 15, 2025 | insidertrades.com

Major Shareholder Sells Thousands of OnKure Therapeutics Shares!

May 14, 2025 | tipranks.com

Promising Developments and Positive Trial Results Reinforce Buy Rating for OnKure Therapeutics

May 9, 2025 | tipranks.com

OnKure increased R&D spending in 1Q with drug trials underway

May 7, 2025 | bizwest.comB

OnKure Therapeutics, Inc.: OnKure Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights

May 6, 2025 | finanznachrichten.de

OnKure Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights | OKUR ...

May 6, 2025 | gurufocus.com

OnKure Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights

May 6, 2025 | gurufocus.com

OnKure Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights

May 6, 2025 | globenewswire.com

OnKure Therapeutics (OKUR) Receives Outperform Rating from Evercore ISI | OKUR Stock News

April 30, 2025 | gurufocus.com

OnKure Therapeutics, Inc. Class A Common Stock (OKUR) Charts

April 16, 2025 | nasdaq.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

APRE, ITRM, MRSN, and OKUR Company Descriptions

Aprea Therapeutics NASDAQ:APRE

$1.58 -0.02 (-1.25%)

Closing price 03:59 PM Eastern

Extended Trading

$1.59 +0.01 (+0.63%)

As of 04:17 PM Eastern

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors. The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.

Iterum Therapeutics NASDAQ:ITRM

$0.68 -0.04 (-5.23%)

Closing price 04:00 PM Eastern

Extended Trading

$0.70 +0.01 (+2.15%)

As of 07:38 PM Eastern

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.

Mersana Therapeutics NASDAQ:MRSN

$7.65 0.00 (0.00%)

Closing price 04:00 PM Eastern

Extended Trading

$7.65 0.00 (0.00%)

As of 06:54 PM Eastern

Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.

OnKure Therapeutics NASDAQ:OKUR

$2.75 -0.07 (-2.48%)

Closing price 04:00 PM Eastern

Extended Trading

$2.74 -0.02 (-0.55%)

As of 04:39 PM Eastern

OnKure Therapeutics, Inc. engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure and computational chemistry driven drug design platform, committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer. It is headquartered in Boulder, CO.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time